Show simple item record

dc.contributor.advisorQuiroga Matamoros, William
dc.contributor.authorMikan Lozano, Angelica Maria
dc.contributor.authorTunjano Rozo, Yineth Camila
dc.contributor.otherArdila Duarte, Gerardo
dc.coverage.spatialBogotaspa
dc.coverage.temporal2017-2020spa
dc.date.accessioned2021-12-28T20:50:52Z
dc.date.available2021-12-28T20:50:52Z
dc.date.issued2021-11-26
dc.identifier.urihttp://hdl.handle.net/10654/39852
dc.description.abstractIntroducción: El cáncer de próstata es uno de los canceres más prevalentes en la actualidad y la segunda causa de muerte relacionada con cáncer en hombres. (1). Dentro de los métodos de tamizaje y diagnóstico, se encuentra la Resonancia magnética multiparamétrica de próstata. (2,3) Este estudio permite caracterizar y localizar las lesiones sugestivas de malignidad, empleando la clasificación PIRADS V2, la cual nos permitirá evaluar la probabilidad de encontrar patología maligna clínicamente significativa, disminuyendo así, el sobretratamiento y la realización de biopsias innecesarias. El objetivo principal de este estudio es predecir los factores relacionados con el diagnóstico de cáncer de próstata en pacientes con resonancia multiparamétrica reportada como PI-RADS V2 3 con antecedente de biopsia previa negativa Métodos: Estudio predictivo multivariable retrospectivo, que se realizó en el Hospital Militar Central de Bogotá entre 2017 y 2020. Se calculó el tamaño de una muestra para proporciones. Se realizó una regresión logística múltiple para el cálculo del OR de cada variable. Se realizaron las pruebas de Chi cuadrado, la prueba de Shapiro-wilk, el test de Mann-Whitney, el criterio de información de Akaike, la prueba exacta de Fisher y se realizó una curva de ROC. Empleando el software estadístico Reals Statistics V7. Resultados: La raza, el antecedente familiar de cáncer de próstata, el tacto rectal, la densidad del PSA y el tiempo de doblaje del PSA, fueron factores predictores de cáncer de próstata con una p estadísticamente significativa de 0.03, 0.007, 0.011,0.005 y 0.013 respectivamente. La edad y la calculadora de riesgo SWOP para cáncer detectable, mostraron una p estadísticamente significativa siendo p 0.048, OR 0.91 [0.82 a 1.01] y p0.049, OR 1.09 [0.99 a 1.20] respectivamente. Discusión: En nuestro estudio, se encontraron como factores predictores de cáncer de próstata la raza, así mismo aquellos pacientes con antecedente familiar, tacto rectal anormal, densidad del PSA > 0.15 y tiempo de doblaje menor de 10 meses. Conclusiones: La raza, el antecedente familiar, el tiempo de doblaje del PSA, la densidad del PSA y las anormalidades al tacto de la próstata deben ser tomados en consideración en el escenario de pacientes con sospecha de cáncer de próstata y con hallazgos en Resonancia magnética multiparametrica de PIRADS V2 3, al momento de tomar la decisión de repetir métodos invasivos de diagnósticospa
dc.description.tableofcontentsINFORMACIÓN DE AUTORES 2 3. RESUMEN 5 4. MARCO TEÓRICO 8 3. IDENTIFICACIÓN Y FORMULACIÓN DEL PROBLEMA 16 4. JUSTIFICACIÓN 17 5. OBJETIVOS 19 A. GENERAL 19 B. ESPECIFICOS 19 6. METODOLOGÍA 20 6.6 Lista de variables 22 7. PLAN DE ANALISIS 27 8. CRONOGRAMA 29 9. PRESUPUESTO 30 10.ASPECTOS ÉTICOS 31 11. RESULTADOS 33 12. DISCUSION 37 13. AGRADECIMIENTOS Y CONFLICTO DE INTERÉS 40 14. REFERENCIAS BIBLIOGRÁFICAS 41spa
dc.format.mimetypeapplicaction/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleFactores predictores relacionados con el diagnóstico de cáncer de próstata en pacientes con resonancia multiparamétrica reportada como PI-RADS V2 3 con antecedente de biopsia previa negativa en el Hospital Militar Central durante los años 2017-2020spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.localTesis/Trabajo de grado - Monografía - Especializaciónspa
dc.description.abstractenglishIntroduction: Prostate cancer is one of the most prevalent cancer and is the second cause of death in men. (1) The multiparametric prostate resonance is one of newest tool for the screening and diagnosis. (2,3) This study allows to characterized and to localized any suspicious lesion, using the PI-RADS V2 score, this one is useful to evaluate the probability to find any clinically significant malignant pathology, thus reducing overtreatment and unnecessary biopsies. The main objective of this study is to predict the factors related to the diagnosis of prostate cancer in patients with multiparametric MRI reported as PI-RADS V2 3 with a previous negative biopsy. Method: Retrospective multivariate predictive study, which was carried out at the Hospital Militar Central de Bogotá between 2017 and 2020. The size of a sample was calculated for proportions. A multiple logistic regression was performed to calculate the OR of each variable. Chi-square tests, the Shapiro-wilk test, the Mann-Whitney test, the Akaike information criterion, Fisher's exact test were performed, and a ROC curve was performed. Using the statistical software Reals Statistics V7 Results: Race, family history of prostate cancer, digital rectal examination, PSA density, and PSA doubling time were predictors of prostate cancer with a statistically significant p of 0.03, 0.007, 0.011, 0.005, and 0.013 respectively. Age and the SWOP risk calculator for detectable cancer showed a statistically significant p being p 0.048, OR 0.91 [0.82 to 1.01] and p0.049, OR 1.09 [0.99 to 1.20] respectively. Discussion: In our study, race was found as predictive factors of prostate cancer, likewise those patients with a family history, abnormal rectal examination, PSA density> 0.15 and doubling time of less than 10 months. Conclusion: Race, family history, PSA doubling time, PSA density and abnormalities to the touch of the prostate should be taken into consideration in the setting of patients with suspected prostate cancer and with multiparametric MRI findings. of PIRADS V2 3, when making the decision to repeat invasive diagnostic methodsspa
dc.title.translatedPredictors factor of prostate cancer in patients with multiparametric prostate resonance PI-RADS V2 3 with previous negative prostate biopsy at Hospital Militar Central between 2017 – 2020spa
dc.subject.keywordsProstatic neoplasmspa
dc.subject.keywordsprostatic-specific antigenspa
dc.subject.keywordsMultiparametric Magnetic Resonance Imagingspa
dc.publisher.programUrologíaspa
dc.creator.degreenameEspecialista en Urologíaspa
dc.subject.decsUROLOGIAspa
dc.subject.decsNEOPLASIAS DE LA PROSTATAspa
dc.subject.decsANTIGENO PROSTATICO ESPECIFICOspa
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyFacultad de Medicinaspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.creativecommonsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.relation.referencesGeneral S, Social S. Guía de práctica clínica ( GPC ) para la detección temprana , seguimiento y rehabilitación del cáncer de próstata. 2013.spa
dc.relation.referencesTurkbey B, Choyke PL. Future Perspectives and Challenges of Prostate MR Imaging. Radiol Clin North Am. 2018;56(2):327–37.spa
dc.relation.referencesTurkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, et al. Prostate cancer: Value of multiparametric MR imaging at 3 T for detection - Histopathologic correlation. Radiology. 2010;255(1):89–99.spa
dc.relation.referencesBrawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195–200.spa
dc.relation.referencesTabayoyong W, Abouassaly R. Prostate Cancer Screening and the Associated Controversy. Surg Clin North Am. 2015;95(5):1023–39.spa
dc.relation.referencesCancer P, Detection E. Prostate Cancer Early Detection Recommendations. 2005;(December 2004):1–3.spa
dc.relation.referencesGjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011;95(1):191–200.spa
dc.relation.referencesIsmail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am [Internet]. 2013;40(4):457–72. Available from: http://dx.doi.org/10.1016/j.ucl.2013.07.012spa
dc.relation.referencesRadtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer—Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol [Internet]. 2017;72(6):888–96. Available from: http://dx.doi.org/10.1016/j.eururo.2017.03.039spa
dc.relation.referencesWeinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol [Internet]. 2016;69(1):16–40. Available from: http://dx.doi.org/10.1016/j.eururo.2015.08.052spa
dc.relation.referencesTorregrosa Andrés A, Otero García M, Sineiro Galiñanes M. Magnetic resonance imaging of the prostate: interpretation using the PI-RADS V2. Radiologia. 2017;59(2):128–38.spa
dc.relation.referencesKumar V, Bora GS, Kumar R, Jagannathan NR. Multiparametric (mp) MRI of prostate cancer. Prog Nucl Magn Reson Spectrosc. 2018;105:23–40.spa
dc.relation.referencesBarrett T, Turkbey B, Choyke PL. PI-RADS version 2: What you need to know. Clin Radiol. 2015;70(11):1165–76.spa
dc.relation.referencesChristidis D, McGrath S, Leaney B, O’Sullivan R, Lawrentschuk N. Interpreting Prostate Multiparametric Magnetic Resonance Imaging: Urologists’ Guide Including Prostate Imaging Reporting and Data System. Urology. 2018;111:136–8.spa
dc.relation.referencesSteinkohl F, Gruber L, Bektic J, Nagele U, Aigner F, Herrmann TRW, et al. Retrospective analysis of the development of PIRADS 3 lesions over time: when is a follow-up MRI reasonable? World J Urol [Internet]. 2018;36(3):367–73. Available from: https://doi.org/10.1007/s00345-017-2135-0spa
dc.relation.referencesZhao C, Gao G, Fang D, Li F, Yang X, Wang H, et al. The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer. Clin Imaging [Internet]. 2016;40(5):885–8. Available from: http://dx.doi.org/10.1016/j.clinimag.2016.04.010spa
dc.relation.referencesLiddell H, Jyoti R, Haxhimolla H. mp-MRI Prostate Characterised PIRADS 3 Lesions are Associated with a Low Risk of Clinically Significant Prostate Cancer – A Retrospective Review of 92 Biopsied PIRADS 3 Lesions. Curr Urol [Internet].2014;8:96-100. Available from: https:// doi.org/10.1159/000365697spa
dc.relation.referencesSheridan, A. D., Nath, S. K., Syed, J. S., Aneja, S., Sprenkle, P. C., Weinreb, J. C., & Spektor, M. (2018). Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI. American Journal of Roentgenology, 210(2), 347–357. doi:10.2214/ajr.17.18516spa
dc.relation.referencesWashino, S., Okochi, T., Saito, K., Konishi, T., Hirai, M., Kobayashi, Y., & Miyagawa, T. (2016). Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU International, 119(2), 225–233. doi:10.1111/bju.13465spa
dc.relation.referencesKotb, A.F., Spaner, S., Crump, T. et al. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy. World J Urol 36, 2021–2025 (2018). https://doi.org/10.1007/s00345-018-2341-4spa
dc.subject.proposalCáncer de próstataspa
dc.subject.proposalResonancia magnética nuclear multiparametricaspa
dc.subject.proposalAntígeno especifico de próstata.spa
dc.publisher.grantorUniversidad Militar Nueva Granadaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1f*
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.instnameinstname:Universidad Militar Nueva Granadaspa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Militar Nueva Granadaspa
dc.identifier.repourlrepourl:https://repository.unimilitar.edu.cospa
dc.rights.localAcceso abiertospa
dc.coverage.sedeMedicinaspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/